Prostate Cancer Prevention

  • Amit M. AlgotarEmail author
  • Anne Cress


Prostate cancer is a major cause of morbidity and mortality for American men. Hence, it is essential to understand the factors that could be helpful in preventing it. Majority of incident cancer follows an indolent trajectory, although significant percent follows an aggressive trajectory leading to considerable morbidity and mortality. Due to this, the emphasis of the current chapter is on secondary rather than primary prevention. Currently available diagnostic modalities are unable to reliably distinguish between aggressive and indolent disease. Hence, efforts need to be made to understand the factor associated with secondary and tertiary prevention of prostate cancer. This chapter systematically reviews literature starting with the changing guidelines, the modifiable risk factors for prostate cancer prevention, factors affecting prostate cancer survivorship, novel avenues for prostate cancer prevention, and finishing with themes to be addressed in the future that could be instrumental in preventing prostate cancer.


Prostate cancer USPSTF guidelines Primary prevention Secondary prevention Tertiary prevention Modifiable risk factors Prostate cancer survivorship Novel risk factors 


  1. Algotar AM et al (2011) Dose-dependent effects of selenized yeast on total selenium levels in prostatic tissue of men with prostate cancer. Nutr Cancer 63(1):1–5PubMedPubMedCentralGoogle Scholar
  2. Algotar AM et al (2013) Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate 73(3):328–335PubMedCrossRefPubMedCentralGoogle Scholar
  3. Allchorne P, Green J (2016) Identifying unmet care needs of patients with prostate cancer to assist with their success in coping. Urol Nurs 36(5):224–232PubMedCrossRefPubMedCentralGoogle Scholar
  4. Andriole GL et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319PubMedPubMedCentralCrossRefGoogle Scholar
  5. Banerji JS et al (2016) Prostate needle biopsy outcomes in the era of the U.S. Preventive Services Task Force recommendation against prostate specific antigen based screening. J Urol 195(1):66–73PubMedCrossRefPubMedCentralGoogle Scholar
  6. Barocas DA et al (2015) Effect of the USPSTF Grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States. J Urol 194(6):1587–1593PubMedCrossRefPubMedCentralGoogle Scholar
  7. Baum RP et al (2016) 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med 57(7):1006–1013PubMedCrossRefPubMedCentralGoogle Scholar
  8. Bluethmann SM, Mariotto AB, Rowland JH (2016) Anticipating the “Silver Tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomark Prev 25(7):1029–1036CrossRefGoogle Scholar
  9. Bonn SE et al (2014) Body mass index and weight change in men with prostate cancer: progression and mortality. Cancer Causes Control 25(8):933–943PubMedCrossRefPubMedCentralGoogle Scholar
  10. Bonn SE et al (2015) Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomark Prev 24(1):57–64CrossRefGoogle Scholar
  11. Bosland MC et al (2013) Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. JAMA 310(2):170–178PubMedPubMedCentralCrossRefGoogle Scholar
  12. Brasky TM et al (2013) Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 105(15):1132–1141PubMedPubMedCentralCrossRefGoogle Scholar
  13. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–591PubMedCrossRefGoogle Scholar
  14. Cao Y, Ma J (2011) Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 4(4):486–501CrossRefGoogle Scholar
  15. Cavarretta I et al (2017) The microbiome of the prostate tumor microenvironment. Eur Urol 72(4):625–631PubMedCrossRefPubMedCentralGoogle Scholar
  16. Chan JM et al (2006) Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 17(2):199–208PubMedCrossRefPubMedCentralGoogle Scholar
  17. Chiang PH, Liu YY (2016) Comparisons of oncological and functional outcomes among radical retropubic prostatectomy, high dose rate brachytherapy, cryoablation and high-intensity focused ultrasound for localized prostate cancer. Springerplus 5(1):1905PubMedPubMedCentralCrossRefGoogle Scholar
  18. Chubak J et al (2012) Providing care for cancer survivors in integrated health care delivery systems: practices, challenges, and research opportunities. J Oncol Pract 8(3):184–189PubMedPubMedCentralCrossRefGoogle Scholar
  19. Clark LC et al (1998) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 81(5):730–734PubMedCrossRefPubMedCentralGoogle Scholar
  20. Cook NR et al (2000) Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians’ Health Study (United States). Cancer Causes Control 11(7):617–626Google Scholar
  21. Discacciati A, Orsini N, Wolk A (2012) Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol 23(7):1665–1671PubMedCrossRefPubMedCentralGoogle Scholar
  22. Drazer MW, Huo D, Eggener SE (2015) National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 33(22):2416–2423PubMedCrossRefPubMedCentralGoogle Scholar
  23. Duffield-Lillico AJ et al (2003) Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91(7):608–612PubMedCrossRefPubMedCentralGoogle Scholar
  24. Eapen RS et al (2017) Impact of the United States Preventive Services Task Force ‘D’ recommendation on prostate cancer screening and staging. Curr Opin Urol 27(3):205–209PubMedCrossRefPubMedCentralGoogle Scholar
  25. Epstein JI et al (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244–252PubMedPubMedCentralGoogle Scholar
  26. Focht BC et al (2014) The Individualized Diet and Exercise Adherence Pilot Trial (IDEA-P) in prostate cancer patients undergoing androgen deprivation therapy: study protocol for a randomized controlled trial. Trials 15:354PubMedPubMedCentralCrossRefGoogle Scholar
  27. Galet C et al (2014) Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy. Cancer Prev Res (Phila) 7(1):97–104CrossRefGoogle Scholar
  28. Gann PH et al (1999) Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 59(6):1225–1230PubMedPubMedCentralGoogle Scholar
  29. Geybels MS et al (2013) Coffee and tea consumption in relation to prostate cancer prognosis. Cancer Causes Control 24(11):1947–1954PubMedCrossRefPubMedCentralGoogle Scholar
  30. Giovannucci E et al (2002) A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94(5):391–398PubMedPubMedCentralCrossRefGoogle Scholar
  31. Hackshaw-McGeagh L et al (2016) Prostate cancer - evidence of exercise and nutrition trial (PrEvENT): study protocol for a randomised controlled feasibility trial. Trials 17(1):123PubMedPubMedCentralCrossRefGoogle Scholar
  32. Haseen F et al (2009) Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review. Prostate Cancer Prostatic Dis 12(4):325–332PubMedCrossRefPubMedCentralGoogle Scholar
  33. Heinonen OP et al (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90(6):440–446PubMedCrossRefPubMedCentralGoogle Scholar
  34. Hewitt M, Stoval E, et al. (2006). From cancer patient to cancer survivor: lost in transition. N.A. PressGoogle Scholar
  35. Huncharek M, Muscat J, Kupelnick B (2008) Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer 60(4):421–441PubMedCrossRefPubMedCentralGoogle Scholar
  36. IARC (2018) IARC monographs on the evaluation of carcinogenic risk of chemicals to man. Available at:
  37. Jacobsen PB, Andrykowski MA (2015) Tertiary prevention in cancer care: understanding and addressing the psychological dimensions of cancer during the active treatment period. Am Psychol 70(2):134–145PubMedCrossRefPubMedCentralGoogle Scholar
  38. Jemal A et al (2015) Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 314(19):2054–2061CrossRefGoogle Scholar
  39. Jemal A et al (2016) Prostate cancer incidence rates 2 years after the US Preventive Services Task Force recommendations against screening. JAMA Oncol 2(12):1657–1660PubMedCrossRefPubMedCentralGoogle Scholar
  40. Jian L, Lee AH, Binns CW (2007) Tea and lycopene protect against prostate cancer. Asia Pac J Clin Nutr 16(Suppl 1):453–457PubMedPubMedCentralGoogle Scholar
  41. Joshu CE et al (2011) Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res (Phila) 4(4):544–551CrossRefGoogle Scholar
  42. Kenfield SA et al (2011a) Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 29(6):726–732PubMedPubMedCentralCrossRefGoogle Scholar
  43. Kenfield SA et al (2011b) Smoking and prostate cancer survival and recurrence. JAMA 305(24):2548–2555PubMedPubMedCentralCrossRefGoogle Scholar
  44. Klein EA et al (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306(14):1549–1556PubMedPubMedCentralCrossRefGoogle Scholar
  45. Kolonel LN et al (2000) Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomark Prev 9(8):795–804Google Scholar
  46. Kurahashi N et al (2008) Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 167(1):71–77PubMedCrossRefPubMedCentralGoogle Scholar
  47. Lippman SM et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301(1):39–51PubMedCrossRefPubMedCentralGoogle Scholar
  48. Ma J et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–1047PubMedPubMedCentralCrossRefGoogle Scholar
  49. Mateo J et al (2017) DNA repair in prostate cancer: biology and clinical implications. Eur Urol 71(3):417–425PubMedCrossRefPubMedCentralGoogle Scholar
  50. McDonald RJ et al (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275(3):772–782PubMedCrossRefPubMedCentralGoogle Scholar
  51. Miller KD et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66(4):271–289PubMedPubMedCentralCrossRefGoogle Scholar
  52. Mondul AM et al (2017) Vitamin D and cancer risk and mortality: state of the science, gaps, and challenges. Epidemiol Rev 39(1):28–48PubMedPubMedCentralCrossRefGoogle Scholar
  53. Namekawa T et al (2015) Prospective evaluation of the safety of transrectal ultrasound-guided transperineal prostate biopsy based on adverse events. Int J Clin Oncol 20(6):1185–1191PubMedCrossRefPubMedCentralGoogle Scholar
  54. NCCN (2016). NCCN guidelines Version 2.2016, SurvivorshipGoogle Scholar
  55. NCCS (2018). Our Mission. Accessed 29 Mar 2018
  56. Ornish D et al (2005) Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174(3):1065–1069. discussion 1069-70PubMedCrossRefPubMedCentralGoogle Scholar
  57. Ornish D et al (2008) Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A 105(24):8369–8374PubMedPubMedCentralCrossRefGoogle Scholar
  58. Ornish D et al (2013) Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol 14(11):1112–1120PubMedCrossRefPubMedCentralGoogle Scholar
  59. Padhani AR et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71(1):81–92PubMedPubMedCentralCrossRefGoogle Scholar
  60. Parsons JK et al (2014) A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Contemp Clin Trials 38(2):198–203PubMedPubMedCentralCrossRefGoogle Scholar
  61. Peisch SF et al (2017) Prostate cancer progression and mortality: a review of diet and lifestyle factors. World J Urol 35(6):867–874PubMedCrossRefPubMedCentralGoogle Scholar
  62. Peters U et al (2007) Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomark Prev 16(5):962–968CrossRefGoogle Scholar
  63. Platz EA et al (2005) Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomark Prev 14(5):1262–1269CrossRefGoogle Scholar
  64. Ploussard G et al (2012) The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance. Eur Urol 61(2):356–362PubMedCrossRefPubMedCentralGoogle Scholar
  65. Pritchard CC et al (2016) Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375(5):443–453PubMedPubMedCentralCrossRefGoogle Scholar
  66. Qin LQ et al (2007) Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. Asia Pac J Clin Nutr 16(3):467–476PubMedPubMedCentralGoogle Scholar
  67. Resnick MJ et al (2015) Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. J Clin Oncol 33(9):1078–1085PubMedCrossRefPubMedCentralGoogle Scholar
  68. Richman EL et al (2010) Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. Am J Clin Nutr 91(3):712–721PubMedCrossRefPubMedCentralGoogle Scholar
  69. Richman EL et al (2011a) Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. Cancer Prev Res (Phila) 4(12):2110–2121CrossRefGoogle Scholar
  70. Richman EL et al (2011b) Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res 71(11):3889–3895PubMedPubMedCentralCrossRefGoogle Scholar
  71. Richman EL et al (2012) Choline intake and risk of lethal prostate cancer: incidence and survival. Am J Clin Nutr 96(4):855–863PubMedPubMedCentralCrossRefGoogle Scholar
  72. Rieken M et al (2015) Association of cigarette smoking and smoking cessation with biochemical recurrence of prostate cancer in patients treated with radical prostatectomy. Eur Urol 68(6):949–956PubMedCrossRefPubMedCentralGoogle Scholar
  73. Rischmann P et al (2017) Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients. Eur Urol 71(2):267–273PubMedCrossRefPubMedCentralGoogle Scholar
  74. Roethke M et al (2012) MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 30(2):213–218PubMedCrossRefPubMedCentralGoogle Scholar
  75. Rubin MA, Girelli G, Demichelis F (2016) Genomic correlates to the newly proposed grading prognostic groups for prostate cancer. Eur Urol 69(4):557–560PubMedCrossRefPubMedCentralGoogle Scholar
  76. Schenk JM et al (2014) Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomark Prev 23(8):1484–1493CrossRefGoogle Scholar
  77. Schroder FH, Roobol MJ (2010) ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol 58(1):46–52PubMedCrossRefPubMedCentralGoogle Scholar
  78. Schroder FH et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328PubMedCrossRefPubMedCentralGoogle Scholar
  79. Sfanos KS et al (2018) The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol 15(1):11–24PubMedCrossRefPubMedCentralGoogle Scholar
  80. Sinha R et al (2009) Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States. Am J Epidemiol 170(9):1165–1177PubMedPubMedCentralCrossRefGoogle Scholar
  81. Skolarus TA et al (2010) The delivery of prostate cancer care in the United States: implications for delivery system reform. J Urol 184(6):2279–2284PubMedCrossRefPubMedCentralGoogle Scholar
  82. Skolarus TA et al (2014) American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 64(4):225–249PubMedCrossRefPubMedCentralGoogle Scholar
  83. Stratton MS et al (2010) Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila) 3(8):1035–1043CrossRefGoogle Scholar
  84. Szymanski KM, Wheeler DC, Mucci LA (2010) Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 92(5):1223–1233PubMedCrossRefPubMedCentralGoogle Scholar
  85. USPSTF (2012). Screening for prostate cancer. Clinical summary of U.S. Preventive Services Task Force RecommendationGoogle Scholar
  86. USPSTF (2017). Draft evidence review: prostate cancer: screening. U.S. Preventive Services Task Force. Accessed Apr 2017
  87. Weinreb JC et al (2016) PI-RADS prostate imaging - reporting and data system: 2015, version 2. Eur Urol 69(1):16–40PubMedCrossRefPubMedCentralGoogle Scholar
  88. Weinstein SJ et al (2007) Serum and dietary vitamin E in relation to prostate cancer risk. Cancer Epidemiol Biomark Prev 16(6):1253–1259CrossRefGoogle Scholar
  89. Wilson KM et al (2011) Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst 103(11):876–884PubMedPubMedCentralCrossRefGoogle Scholar
  90. Wilson KM et al (2016) Meat, fish, poultry, and egg intake at diagnosis and risk of prostate cancer progression. Cancer Prev Res (Phila) 9(12):933–941CrossRefGoogle Scholar
  91. World Cancer Research Fund International (2014) Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Prostate Cancer. Available at:
  92. Xu Y et al (2014) Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol 140(9):1465–1477PubMedCrossRefPubMedCentralGoogle Scholar
  93. Zheng J et al (2011) Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. Nutr Cancer 63(5):663–672PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Family and Community Medicine, School of MedicineUniversity of Arizona, University of Arizona Cancer CenterTucsonUSA
  2. 2.Department of Cellular and Molecular Medicine, School of MedicineUniversity of Arizona, University of Arizona Cancer CenterTucsonUSA

Personalised recommendations